We are pleased to report that Frontiers in Nutrition has published the results of our most recent clinical trial:
“An A2 β-casein infant formula with high sn-2 palmitate and casein phosphopeptides supports adequate growth, improved stool consistency, and bone strength in healthy, term Chinese infants: a randomized, double-blind, controlled clinical trial.”
This study evaluated the effects of an A2 β-casein cow’s milk infant formula enriched with casein phosphopeptides (CPP) and high sn-2 palmitate (54% of total palmitate at sn-2) compared to a standard cow’s milk formula with low sn-2 palmitate (29%). A human milk group served as an additional reference.
Key findings:
-
Growth: Infants in the investigational formula and human milk groups showed greater body length and head circumference growth compared to the control formula group.
-
Digestive comfort: Both groups also had softer stools, higher stool frequency, and reduced constipation, abdominal discomfort, and crying time.
-
Bone health: At 150 days of age, there was an improvement in the bone quality index and bone speed of sound.
-
Tolerability: The investigational formula was well tolerated, with fewer adverse events reported compared to the control group.
Overall, the results demonstrate that an A2 β-casein formula enriched with high sn-2 palmitate and CPP supports adequate growth, gastrointestinal comfort, and bone development in healthy term infants—showing benefits comparable to human milk.